Inhibiting mTORC1/2 during chemotherapy helps preserve ovarian function and fertility in mice, offering a potential approach to reducing chemotherapy-induced reproductive ageing and supporting healthspan.
March 2017 – Biological Science
Key Takeaways
- Targeting mTORC1/2 pathways can preserve ovarian function during chemotherapy: Reducing mTORC1/2 activity prevents damage to ovarian tissues, helping maintain reproductive health and delaying reproductive ageing caused by chemotherapy
- Preserving fertility supports overall health and longevity: By safeguarding ovarian function, it is possible to improve hormonal balance and reduce the risk of age-related diseases linked to reproductive ageing
- Chemotherapy-induced reproductive ageing can be mitigated: Interventions targeting cellular pathways during treatment can minimise long-term impacts on fertility and delay age-associated physiological decline
Approaches that mitigate ovarian damage not only protect fertility but may also contribute to extended overall vitality and reduced systemic ageing effects.
Read the article at: Goldman, Kenneth N., et al. “mTORC1/2 inhibition preserves fertility during ovarian damage by chemotherapy.” Proceedings of the National Academy of Sciences, vol. 114, no. 1, 2017, doi:10.1073/pnas.1617233114.